IP Library › Granted Patent US 10,821,072
Granted Patent B2
US 10,821,072 · App. 16/149,032 · Granted Nov 3, 2020

Needle assisted jet injection administration of testosterone compositions

Inventors: Paul K. Wotton (Newtown, PA); Kaushik J. Dave (Edison, NJ); John W. Hayes (Chaska, MN); Peter L. Sadowski (Woodbury, MN); Hermanus L. Jooste (Wayne, PA); Jonathan Jaffe (Annandale, NJ)
Assignee: Antares Pharma, Inc.
A61K9/0019A61K31/56A61K31/568A61M5/002A61M5/2033A61M5/30A61M5/3153A61M5/3202A61M5/326A61M5/425A61M5/44A61M37/00A61M2005/206A61M2005/2013A61M2005/2073A61M2205/364A61M2205/3613A61M2205/3673
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,821,072
App. No.
16/149,032
Granted
Nov 3, 2020
Kind
B2
Abstract

The present invention provides compositions and methods for treating a subject in need of treatment with testosterone, including introducing testosterone into the subject subcutaneously, intradermally, or intramuscularly, from a needle assisted jet injection device.

Claims (23)

1. A method of administering testosterone comprising:

subcutaneously administering a preservative-free composition comprising a unit dose of testosterone or a pharmaceutically acceptable ester or salt thereof in a pharmaceutically acceptable carrier to a mammal,

wherein a plasma level of testosterone remains above about 200 ng/dl for a predetermined period of time after administration,

and wherein administering the preservative-free composition comprises at least one injection via a powered injector comprising a housing, a chamber disposed within the housing, the chamber configured to receive the preservative-free composition, and a needle operatively associated with the chamber.

2. The method of claim 1 , wherein the at least one injection consists of two injections.

3. The method of claim 1 , wherein the at least one injection consists of three injections.

4. The method of claim 1 , wherein the at least one injection consists of more than three injections.

5. The method of claim 1 , wherein the plasma level of testosterone remains above a value selected from the group consisting of about 300 ng/dl, about 350 ng/dl, about 400 ng/dl, about 450 ng/dl, about 500 ng/dl, about 550 ng/dl, about 600 ng/dl, about 650 ng/dl, about 700 ng/dl, about 750 ng/dl, about 800 ng/dl, about 850 ng/dl, about 900 ng/dl, about 950 ng/dl, about 1000 ng/dl, about 1050 ng/dl, and about 1100 ng/dl for the predetermined period of time.

6. The method of claim 1 , wherein the predetermined period of time is at least 1 hour.

7. The method of claim 1 , wherein the predetermined period of time is at least 12 hours.

8. The method of claim 1 , wherein the predetermined period of time period is at least 1 day.

9. The method of claim 1 , wherein the predetermined period of time is at least 6 days.

10. The method of claim 1 , wherein the predetermined period of time is at least 7 days.

11. The method of claim 1 , wherein the predetermined period of time is at least 9 days.

12. The method of claim 1 , wherein the predetermined period of time is at least 11 days.

13. The method of claim 1 , wherein the predetermined period of time is at least 13 days.

14. The method of claim 1 , wherein the predetermined period of time is at least 15 days.

15. The method of claim 1 , wherein the predetermined period of time is at least 20 days.

16. The method of claim 1 , wherein the predetermined period of time is at least 25 days.

17. The method of claim 1 , wherein the preservative-free composition comprises a liquid composition.

18. The method of claim 1 , wherein the administering of the preservative-free composition includes administering a single unit dose.

19. The method of claim 1 , wherein the plasma level of testosterone does not exceed about 1800 ng/dl for the predetermined period of time after administration.

20. The method of claim 1 , wherein the preservative-free composition is substantially free of precipitate.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 30, 2022
From: WOTTON, PAUL K.; DAVE, KAUSHIK J.; HAYES, JOHN W.; SADOWSKI, PETER L.; JOOSTE, HERMANUS L.; JAFFE, JONATHAN
To: ANTARES PHARMA, INC.
Reel/Frame 059439/0225 →
Continuity (7)
Continuation 15238901 · Aug 17, 2016
Continuation 13857859 · Apr 5, 2013
Provisional Application 61783444 · Mar 14, 2013
Provisional Application 61776283 · Mar 11, 2013
Provisional Application 61763395 · Feb 11, 2013
Provisional Application 61621298 · Apr 6, 2012
Related Publication 20190030260A1 · Jan 31, 2019
Cited By (6)
US 12,453,822 US 12,527,802 US 12,551,633 US 12,558,495 US 12,569,625 US 12,691,228